John C. Kath

4.7k citations

30 papers · 2.4k indexed · h-index 19

Co-authors: Clayton H. Heathcock Roger B. Ruggeri K.S. Gajiwala Alma L. Burlingame Jack Taunton Xiaobo Wan Lyn H. Jones Michael J. Luzzio
Topics: Protein Degradation and Inhibitors (5 papers)HER2/EGFR in Cancer Research (5 papers)Monoclonal and Polyclonal Antibodies Research (5 papers)
Cited by: Immunology and Allergy Organic Chemistry Molecular Biology
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Journal of Biological Chemistry
Partner nations: United States Poland Germany

In The Last Decade

John C. Kath

29 papers receiving 2.4k citations

Peers

Countries citing papers authored by John C. Kath

Since Specialization

Citations

This map shows the geographic impact of John C. Kath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Kath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Kath more than expected).

Fields of papers citing papers by John C. Kath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Kath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Kath. The network helps show where John C. Kath may publish in the future.

Co-authorship network of co-authors of John C. Kath

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Kath. A scholar is included among the top collaborators of John C. Kath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Kath. John C. Kath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predicting Flow in Fracture Networks With Quantum Algorithms 2025 ·Water Resources Research ·John C. Kath,John Golden,Allon G. Percus,Daniel O’Malley	0
2	Bayesian learning of gas transport in three-dimensional fracture networks 2024 ·Computers & Geosciences ·Yingqi Shi,(unknown),John C. Kath,(unknown),(unknown),Allon G. Percus,Jeffrey D. Hyman,Kelly R. Moran,(unknown),Matthew Sweeney,Hari Viswanathan,Philip H. Stauffer	1
3	Addressing quantum’s “fine print” with efficient state preparation and information extraction for quantum algorithms and geologic fracture networks 2024 ·Scientific Reports ·(unknown),John C. Kath,John Golden,Allon G. Percus,Daniel O’Malley	2
4	Reversible lysine-targeted probes reveal residence time-based kinase selectivity 2022 ·Nature Chemical Biology ·Tangpo Yang,Adolfo Cuesta,Xiaobo Wan,Gregory B. Craven,Brad Hirakawa,(unknown),(unknown),John C. Kath,John D. Lapek,Sherry Niessen,Alma L. Burlingame,Jordan D. Carelli,Jack Taunton	63
5	Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors 2017 ·Cell chemical biology ·Sherry Niessen,Melissa M. Dix,(unknown),Zachary E. Potter,Shuyan Lu,Oleg Brodsky,Simon Planken,Douglas C. Behenna,Chau Almaden,K.S. Gajiwala,Kevin Ryan,Rose Ann Ferre,Michael R. Lazear,Matthew M. Hayward,John C. Kath,Benjamin F. Cravatt	77
6	Chemoselective Preparation of Clickable Aryl Sulfonyl Fluoride Monomers: A Toolbox of Highly Functionalized Intermediates for Chemical Biology Probe Synthesis 2016 ·ChemBioChem ·Olugbeminiyi Fadeyi,Mihir D. Parikh,(unknown),Robert E. Kyne,Alexandria P. Taylor,Inish O’Doherty,Stephen E. Kaiser,(unknown),Sherry Niessen,(unknown),Scott L. Weinrich,John C. Kath,Lyn H. Jones,Ralph P. Robinson	46
7	A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors 2014 ·Nature Chemical Biology ·Bryan Lanning,Landon R. Whitby,Melissa M. Dix,John Douhan,A. Gilbert,Erik C. Hett,Theodore Johnson,(unknown),John C. Kath,Sherry Niessen,Lee R. Roberts,Mark E. Schnute,Chu Wang,Jonathan J. Hulce,Baoxian Wei,Laurence O. Whiteley,Matthew M. Hayward,Benjamin F. Cravatt	265
8	Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance 2013 ·Proceedings of the National Academy of Sciences ·Phillip A. Schwartz,Petr Kuzmič,James Solowiej,Simon Bergqvist,Ben Bolaños,Chau Almaden,Asako Nagata,Kevin Ryan,Junli Feng,Deepak Dalvie,John C. Kath,Meirong Xu,Revati Wani,Brion W. Murray	197
9	Selective addition of amines to 5-trifluoromethyl-2,4-dichloropyrimidine induced by Lewis acids 2013 ·Tetrahedron Letters ·(unknown),John C. Kath,Michael J. Luzzio,(unknown),Martin A. Berliner,Matthew D. Wessel	17
10	Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition 2012 ·Structure ·K.S. Gajiwala,Junli Feng,Rose Ann Ferre,Kevin Ryan,Oleg Brodsky,Scott L. Weinrich,John C. Kath,Al Stewart	140
11	Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery 2011 ·Journal of Computer-Aided Molecular Design ·M. Catherine Johnson,Qiyue Hu,Laura Lingardo,Rose Ann Ferre,S.E. Greasley,Jiangli Yan,John C. Kath,Ping Chen,Jacques Ermolieff,Gordon Alton	15
12	Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor 2007 ·Cancer Research ·Jitesh P. Jani,Richard S. Finn,Mary E. Campbell,Kevin Coleman,Richard D. Connell,Nicolas Currier,Erling O. Emerson,Eugenia Floyd,Shawn Harriman,John C. Kath,Joel Morris,James D. Moyer,Leslie R. Pustilnik,Kristina Rafidi,Sherry L. Ralston,Ann Marie Rossi,Stefanus J. Steyn,Larry E. Wagner,Steven M. Winter,Samit K. Bhattacharya	62
13	Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor 2007 ·Journal of Biological Chemistry ·Jill K. Slack‐Davis,Karen H. Martin,Robert W. Tilghman,Marcin Iwanicki,Ethan Ung,Christopher Autry,Michael J. Luzzio,Beth Cooper,John C. Kath,W. Gregory Roberts,J. Thomas Parsons	408
14	Process Development of CP-481715, a Novel CCR1 Antagonist 2005 ·Organic Process Research & Development ·Bryan Li,Brian M. Andresen,Matthew F. Brown,(unknown),(unknown),Michel Couturier,Eric L. Dias,Frank J. Urban,V. John Jasys,John C. Kath,William S. Kissel,(unknown),(unknown),Joanna T. Negri,Christopher S. Poss,John L. Tucker,David C. Whritenour,Kathleen S. Zandi	9
15	Potent small molecule CCR1 antagonists 2004 ·Bioorganic & Medicinal Chemistry Letters ·John C. Kath,William H. Brissette,Matthew F. Brown,Maryrose J. Conklyn,(unknown),Peter H. Dorff,Ronald P. Gladue,Brett M. Lillie,Paul D. Lira,(unknown),William H. Martin,Eric B. McElroy,(unknown),Timothy Paradis,Christopher S. Poss,Ingrid A. Stock,Laurie Tylaska,(unknown)	17
16	The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template 2004 ·Bioorganic & Medicinal Chemistry Letters ·John C. Kath,(unknown),Ronald P. Gladue,William H. Martin,Eric B. McElroy,Ingrid A. Stock,Laurie Tylaska,(unknown)	17
17	The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. 2003 ·PubMed ·Elsa G. Barbacci,Leslie R. Pustilnik,Ann Marie Rossi,Erling O. Emerson,(unknown),Brian P. Boscoe,Eric Cox,Kenneth K. Iwata,Jitesh P. Jani,(unknown),John C. Kath,Zhengyu Liu,James D. Moyer	40
18	Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor 2003 ·Biochemical and Biophysical Research Communications ·Samit K. Bhattacharya,Eric Cox,John C. Kath,Alan M. Mathiowetz,Joel Morris,James D. Moyer,Leslie R. Pustilnik,(unknown),(unknown),Chunyan Su,Matthew D. Wessel	16
19	CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases 2003 ·Journal of Biological Chemistry ·Ronald P. Gladue,Laurie Tylaska,William H. Brissette,Paul D. Lira,John C. Kath,Christopher S. Poss,Matthew F. Brown,Timothy Paradis,Maryrose J. Conklyn,(unknown),(unknown),Brett M. Lillie,(unknown),(unknown),Eric B. McElroy,William H. Martin,Ingrid A. Stock,Richard M. Shepard,Henry J. Showell,Kuldeep Neote	59
20	UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation 1999 ·British Journal of Pharmacology ·Douglas C. Hanson,Angela Nguyen,Robert J. Mather,Heiko Rauer,Kevin M. Koch,Laurence E. Burgess,James P. Rizzi,Carol Donovan,(unknown),Paul C. Canniff,Ann Cunningham,(unknown),(unknown),John C. Kath,George A. Gutman,Michael D. Cahalan,Stephan Grissmer,(unknown)	62

About John C. Kath

John C. Kath is a scholar working on Organic Chemistry, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 30 papers that have together received 2.4k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (5 papers), HER2/EGFR in Cancer Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). The work is most often cited by research in Immunology and Allergy (249 citations), Organic Chemistry (905 citations) and Molecular Biology (1.5k citations). John C. Kath has collaborated with scholars based in United States, Poland and Germany. Frequent co-authors include Clayton H. Heathcock, Roger B. Ruggeri, K.S. Gajiwala, Alma L. Burlingame, Jack Taunton, Xiaobo Wan, Lyn H. Jones, Michael J. Luzzio, Ethan Ung and W. Gregory Roberts. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact